Response of Estrogen-Receptor-Positive Metastatic Breast Cancer to Olaparib in Late-Line Therapy

被引：0

作者：

Kumeta, Toko ^{[1
]}

Matsunuma, Ryoichi ^{[1
]}

Yamaguchi, Kei ^{[1
]}

Hayami, Ryosuke ^{[1
]}

Tsuneizumi, Michiko ^{[1
]}

机构：

[1] Shizuoka Prefectural Gen Hosp, Shizuoka Prefectural Hosp Org, Dept Breast Surg, Shizuoka, Japan

来源：

CASE REPORTS IN ONCOLOGY | 2019年 / 12卷 / 03期

关键词：

Olaparib; Breast cancer; BRCA; Late line; OVARIAN CANCERS; BRCA2; MUTATIONS; PREVALENCE; SERIES;

D O I：

10.1159/000503858

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Monotherapy with olaparib provides significant benefits over standard therapy in patients with a germline BRCA mutation and human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer, who had two or fewer previous chemotherapeutic regimens for metastatic disease. Olaparib was approved on July 2, 2018, in Japan for the treatment of patients with metastatic breast cancer with a BRCA mutation and HER2-negative status. Thus, the current experience with this drug is relatively limited. In this article, we report a case of luminal-type metastatic breast cancer harboring a BRCA1 mutation detected through BRACAnalysis (Myriad Genetics). Despite the late-line treatment, in this patient, olaparib was effective against metastatic breast cancer.

引用

页码：814 / 819

页数：6

共 11 条

[1] Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy [J].

Farmer, H ;

McCabe, N ;

Lord, CJ ;

Tutt, ANJ ;

Johnson, DA ;

Richardson, TB ;

Santarosa, M ;

Dillon, KJ ;

Hickson, I ;

Knights, C ;

Martin, NMB ;

Jackson, SP ;

Smith, GCM ;

Ashworth, A .

NATURE, 2005, 434 (7035) :917-921

[2] PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies [J].

Lee, J-m. ;

Ledermann, J. A. ;

Kohn, E. C. .

ANNALS OF ONCOLOGY, 2014, 25 (01) :32-40

[3] Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer [J].

Loman, N ;

Johannsson, O ;

Kristoffersson, U ;

Olsson, H ;

Borg, Å .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (16) :1215-1223

[4] A STRONG CANDIDATE FOR THE BREAST AND OVARIAN-CANCER SUSCEPTIBILITY GENE BRCA1 [J].

MIKI, Y ;

SWENSEN, J ;

SHATTUCKEIDENS, D ;

FUTREAL, PA ;

HARSHMAN, K ;

TAVTIGIAN, S ;

LIU, QY ;

COCHRAN, C ;

BENNETT, LM ;

DING, W ;

BELL, R ;

ROSENTHAL, J ;

HUSSEY, C ;

TRAN, T ;

MCCLURE, M ;

FRYE, C ;

HATTIER, T ;

PHELPS, R ;

HAUGENSTRANO, A ;

KATCHER, H ;

YAKUMO, K ;

GHOLAMI, Z ;

SHAFFER, D ;

STONE, S ;

BAYER, S ;

WRAY, C ;

BOGDEN, R ;

DAYANANTH, P ;

WARD, J ;

TONIN, P ;

NAROD, S ;

BRISTOW, PK ;

NORRIS, FH ;

HELVERING, L ;

MORRISON, P ;

ROSTECK, P ;

LAI, M ;

BARRETT, JC ;

LEWIS, C ;

NEUHAUSEN, S ;

CANNONALBRIGHT, L ;

GOLDGAR, D ;

WISEMAN, R ;

KAMB, A ;

SKOLNICK, MH .

SCIENCE, 1994, 266 (5182) :66-71

[5] Prevalence and differentiation of hereditary breast and ovarian cancers in Japan [J].

Nakamura, Seigo ;

Takahashi, Masato ;

Tozaki, Mitsuhiro ;

Nakayama, Takahiro ;

Nomizu, Tadashi ;

Miki, Yoshio ;

Murakami, Yoshie ;

Aoki, Daisuke ;

Iwase, Takuji ;

Nishimura, Seiichiro ;

Yamauchi, Hideko ;

Ohsumi, Shozo ;

Baba, Shinichi ;

Shimizu, Tadao .

BREAST CANCER, 2015, 22 (05) :462-468

[6] Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer [J].

Risch, HA ;

McLaughlin, JR ;

Cole, DEC ;

Rosen, B ;

Bradley, L ;

Kwan, E ;

Jack, E ;

Vesprini, DJ ;

Kuperstein, G ;

Abrahamson, JLA ;

Fan, I ;

Wong, B ;

Narod, SA .

AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 68 (03) :700-710

[7] Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A kin-cohort study in Ontario, Canada [J].

Risch, Harvey A. ;

McLaughlin, John R. ;

Cole, David E. C. ;

Rosen, Barry ;

Bradley, Linda ;

Fan, Isabel ;

Tang, James ;

Li, Song ;

Zhang, Shiyu ;

Shaw, Patricia A. ;

Narod, Steven A. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (23) :1694-1706

[8] OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer [J].

Robson, M. E. ;

Tung, N. ;

Conte, P. ;

Im, S-A ;

Senkus, E. ;

Xu, B. ;

Masuda, N. ;

Delaloge, S. ;

Li, W. ;

Armstrong, A. ;

Wu, W. ;

Goessl, C. ;

Runswick, S. ;

Domchek, S. M. .

ANNALS OF ONCOLOGY, 2019, 30 (04) :558-566

[9] Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation [J].

Robson, Mark ;

Im, Seock-Ah ;

Senkus, Elzbieta ;

Xu, Binghe ;

Domchek, Susan M. ;

Masuda, Norikazu ;

Delaloge, Suzette ;

Li, Wei ;

Tung, Nadine ;

Armstrong, Anne ;

Wu, Wenting ;

Goessl, Carsten ;

Runswick, Sarah ;

Conte, Pierfranco .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (06) :523-533

[10] Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial [J].

Tutt, Andrew ;

Robson, Mark ;

Garber, Judy E. ;

Domchek, Susan M. ;

Audeh, M. William ;

Weitzel, Jeffrey N. ;

Friedlander, Michael ;

Arun, Banu ;

Loman, Niklas ;

Schmutzler, Rita K. ;

Wardley, Andrew ;

Mitchell, Gillian ;

Earl, Helena ;

Wickens, Mark ;

Carmichael, James .

LANCET, 2010, 376 (9737) :235-244

← 1 2 →